Company: ARTL
Filing Date: 2025-10-01
Form Type: 424B5
Source: 0001640334-25-001763
Chunk: 40

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-01
Form: 424B5
Chunk 40
---
 directly to you, through agents or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement. The price to the public of those securities and the net proceeds we expect to receive from that sale will also be set forth in a prospectus supplement.

Our common stock is listed on the Nasdaq Capital Market under the symbol “ARTL.” Each prospectus supplement will indicate whether the securities offered thereby will be listed on any securities exchange. As of June 30, 2023, the aggregate market value of our common stock held by our non-affiliates, as calculated pursuant to the rules of the Securities and Exchange Commission, was approximately $5.68 million, based upon 2,855,688 shares of our outstanding common stock held by non-affiliates at the per share price of $1.99, the closing sale price of our common stock on the Nasdaq Capital Market on June 30, 2023. Pursuant to General Instruction I.B.6 of Form S‑3, in no event will we sell securities in a public offering with a value exceeding more than one‑third of our “public float” (the market value of our common stock held by our non-affiliates) in any 12‑month period so long as our public float remains below $75.0 million. We have not sold any securities in reliance on General Instruction I.B.6 of Form S‑3 during the 12 calendar months prior to and including the date of this prospectus.

Investing in these securities involves risks. Please carefully read the information under the headings “Risk Factors” beginning on page 9 of this prospectus and “Item 1A – Risk Factors” of our most recent report on Form 10-K or 10-Q that is incorporated by reference in this prospectus before you invest in our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is July 14, 2023.</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                     |     | Page |
| About this Prospectus               |     |    3 |
| Prospectus Summary                  |     |    4 |
| Risk Factors                        |     |    9 |